|
Exposure to study opioids and propofol during the maintenance phase (intent to treat population) |
||
| Maintenance phase |
Remifentanil (n = 77) |
Fentanyl (n = 75) |
|
|
||
| Median duration of study opioid infusion (hours; range) |
13.7 (2.7–73.0) |
14.2 (0.3–73.3) |
| Weighted mean study opioid infusion rate (μg/kg per hour; range) |
9.4 (2.3–22.8) |
1.8 (0.5–6.0) |
| Number of patients receiving the study drug infusion for >24 hours |
11 (14%) |
10 (13%) |
| Number of patients who received a propofol infusion |
27 (35%) |
30 (40%) |
| Mean time from starting the opioid infusion to starting the propofol infusion (hours; range) |
6.6 (0.2–55.6) |
5.9 (0.2–38.6) |
| Median duration of propofol infusion (hours; range) |
9.4 (0.6–53.3) |
12.0 (2.5–72.3) |
| Mean % of time patients received a propofol infusion (range) during the maintenance phase |
62.8 (3.8–98.9) |
76.1 (26.9–99.0) |
| Median total propofol dose (mg; range) |
378.4 (15.8–4690.8) |
683.0 (30.0–11323.3) |
| Weighted mean infusion rate of propofol (mg/kg per hour; range) |
0.7 (0.1–2.7) |
0.8 (0.2–2.5) |
| Number of patients receiving the following numbers of propofol bolus doses |
(n = 27) |
(n = 30) |
| 0 |
18 (67%) |
14 (47%) |
| 1–3 |
8 (30%) |
11 (37%) |
| 4–6 |
1 (4%) |
4 (13%) |
| ≥ 7 |
0 |
1 (3%) |
| Number of patients receiving the following numbers of propofol rate increases |
(n = 27) |
(n = 30) |
| 0 |
17 (63%) |
6 (20%) |
| 1–3 |
5 (19%) |
14 (47%) |
| 4–6 |
3 (11%) |
5 (17%) |
| ≥ 7 |
2 (7%) |
5 (17%) |
| Number (%) of patients receiving the following numbers of propofol rate decreases |
(n = 27) |
(n = 30) |
| 0 |
16 (59%) |
18 (60%) |
| 1–3 |
9 (33%) |
8 (27%) |
| 4–6 |
2 (7%) |
3 (10%) |
| ≥ 7 |
0 (0%) |
1 (3%) |
Muellejans et al. Critical Care 2004 8:R1 doi:10.1186/cc2398 |
||